PTX 100
Alternative Names: GGTI-2418; PTX-100Latest Information Update: 19 Jan 2024
Price :
$50 *
At a glance
- Originator H. Lee Moffitt Cancer Center and Research Institute; University of South Florida; Yale University
- Developer Prescient Therapeutics
- Class Amides; Antineoplastics; Imidazoles; Pentanoic acids; Peptidomimetics; Piperazines; Small molecules
- Mechanism of Action Geranylgeranyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Solid tumours
Most Recent Events
- 09 Dec 2023 Safety, efficacy and pharmacodynamics data from a Phase-I clinical trial in Cancer presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 28 Oct 2022 No recent reports of development identified for phase-I development in Cancer(Late-stage disease) in Australia (IV, Infusion)
- 28 Sep 2022 No recent reports of development identified for phase-I development in Solid-tumours(Metastatic disease) in USA